Display options
Cite
Ratto-Kim S, Yoon IK, Paris RM, et al. The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. Front Immunol. 2018;9:1397doi: 10.3389/fimmu.2018.01397.
Ratto-Kim, S., Yoon, I. K., Paris, R. M., Excler, J. L., Kim, J. H., & O'Connell, R. J. (2018). The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. Frontiers in immunology, 91397. https://doi.org/10.3389/fimmu.2018.01397
Ratto-Kim, Silvia, et al. "The US Military Commitment to Vaccine Development: A Century of Successes and Challenges." Frontiers in immunology vol. 9 (2018): 1397. doi: https://doi.org/10.3389/fimmu.2018.01397
Ratto-Kim S, Yoon IK, Paris RM, Excler JL, Kim JH, O'Connell RJ. The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. Front Immunol. 2018 Jun 21;9:1397. doi: 10.3389/fimmu.2018.01397. eCollection 2018. PMID: 29977239; PMCID: PMC6021486.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2018 Jun 21;9:1397. doi: 10.3389/fimmu.2018.01397. eCollection 2018.

The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.

Frontiers in immunology

Silvia Ratto-Kim, In-Kyu Yoon, Robert M Paris, Jean-Louis Excler, Jerome H Kim, Robert J O'Connell

Affiliations

  1. International Vaccine Institute, Seoul, South Korea.
  2. GSK Vaccines, Rockville, MD, United States.
  3. Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.

PMID: 29977239 PMCID: PMC6021486 DOI: 10.3389/fimmu.2018.01397

Abstract

The US military has been a leading proponent of vaccine development since its founding. General George Washington ordered the entire American army to be variolated against smallpox after recognizing the serious threat that it posed to military operations. He did this on the recommendation from Dr. John Morgan, the physician-in-chief of the American army, who wrote a treatise on variolation in 1776. Although cases of smallpox still occurred, they were far fewer than expected, and it is believed that the vaccination program contributed to victory in the War of Independence. Effective military force requires personnel who are healthy and combat ready for worldwide deployment. Given the geography of US military operations, military personnel should also be protected against diseases that are endemic in potential areas of conflict. For this reason, and unknown to many, the US military has strongly supported vaccine research and development. Four categories of communicable infectious diseases threaten military personnel: (1) diseases that spread easily in densely populated areas (respiratory and dysenteric diseases); (2) vector-borne diseases (disease carried by mosquitoes and other insects); (3) sexually transmitted diseases (hepatitis, HIV, and gonorrhea); and (4) diseases associated with biological warfare. For each category, the US military has supported research that has provided the basis for many of the vaccines available today. Although preventive measures and the development of drugs have provided some relief from the burden of malaria, dengue, and HIV, the US military continues to fund research and development of prophylactic vaccines that will contribute to force health protection and global health. In the past few years, newly recognized infections with Zika, severe acute respiratory syndrome, Middle East respiratory syndrome viruses have pushed the US military to fund research and fast track clinical trials to quickly and effectively develop vaccines for emerging diseases. With US military personnel present in every region of the globe, one of the most cost-effective ways to maintain military effectiveness is to develop vaccines against prioritized threats to military members' health.

Keywords: army; development; history; military medicine; vaccines

References

  1. Vaccine. 2014 Sep 8;32(40):5156-62 - PubMed
  2. N Engl J Med. 2012 Dec 13;367(24):2284-95 - PubMed
  3. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1199-203 - PubMed
  4. J Infect Dis. 2003 Jul 15;188(2):219-27 - PubMed
  5. Clin Infect Dis. 2005 Feb 15;40(4):519-25 - PubMed
  6. Am J Prev Med. 2015 Dec;49(6 Suppl 4):S383-90 - PubMed
  7. Wkly Epidemiol Rec. 2016 Jul 29;91(30):349-64 - PubMed
  8. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S4-8 - PubMed
  9. Vaccine. 2009 Nov 5;27 Suppl 4:D16-22 - PubMed
  10. Curr Opin Infect Dis. 2013 Oct;26(5):429-34 - PubMed
  11. Am J Trop Med Hyg. 2017 Jun;96(6):1325-1337 - PubMed
  12. J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254-61 - PubMed
  13. J Fam Pract. 2003 Jan;52(1 Suppl):S56-61 - PubMed
  14. J Infect Dis. 1999 Aug;180(2):290-8 - PubMed
  15. Pathol Biol (Paris). 2015 Jun;63(3):144-51 - PubMed
  16. Nat Med. 2016 Jun;22(6):614-23 - PubMed
  17. J Infect Dis. 2002 Apr 15;185(8):1155-64 - PubMed
  18. J Exp Med. 1969 Jun 1;129(6):1307-26 - PubMed
  19. N Engl J Med. 2011 Nov 17;365(20):1863-75 - PubMed
  20. Expert Rev Vaccines. 2012 May;11(5):511-3 - PubMed
  21. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2395-400 - PubMed
  22. Science. 2016 Jul 22;353(6297):353-4 - PubMed
  23. Am J Trop Med Hyg. 2018 Mar;98(3):849-856 - PubMed
  24. Expert Rev Vaccines. 2015;14(9):1167-79 - PubMed
  25. Clin Infect Dis. 2002 Jun 15;34(Suppl 4):S145-69 - PubMed
  26. Emerg Infect Dis. 2012 Apr;18(4):623-30 - PubMed
  27. Vaccine. 2011 Sep 23;29(42):7229-41 - PubMed
  28. MMWR Morb Mortal Wkly Rep. 2017 May 05;66(17):457-459 - PubMed
  29. Lancet. 2012 Nov 3;380(9853):1559-67 - PubMed
  30. J Infect Dis. 1983 Jun;147(6):1099 - PubMed
  31. Am J Prev Med. 2015 Dec;49(6 Suppl 4):S319-33 - PubMed
  32. Vaccine. 2012 Oct 19;30(47):6713-20 - PubMed
  33. N Engl J Med. 1986 Sep 4;315(10):601-6 - PubMed
  34. J Exp Med. 1969 Jun 1;129(6):1367-84 - PubMed
  35. Hum Vaccin. 2011 Jun;7(6):674-84 - PubMed
  36. N Engl J Med. 2018 Feb 14;:null - PubMed
  37. Nature. 1983 Apr 7;302(5908):536-8 - PubMed
  38. Mil Med. 2004 Aug;169(8):588-93 - PubMed
  39. J Infect Dis. 2001 May 1;183(9):1343-52 - PubMed
  40. N Engl J Med. 2015 Jan 8;372(2):113-23 - PubMed
  41. J Infect Dis. 2017 Dec 16;216(suppl_10):S957-S963 - PubMed
  42. Vaccine. 2015 Feb 18;33(8):954-65 - PubMed
  43. Expert Rev Vaccines. 2008 Oct;7(8):1225-37 - PubMed
  44. Am J Trop Med Hyg. 2018 May;98(5):1435-1443 - PubMed
  45. Am J Trop Med Hyg. 2015 Sep;93(3):441-53 - PubMed
  46. PLoS One. 2008 Apr 23;3(4):e1993 - PubMed
  47. Ann Intern Med. 1969 Jan;70(1):150-3 - PubMed
  48. N Engl J Med. 1997 Jan 9;336(2):86-91 - PubMed
  49. J Infect Dis. 2017 Nov 27;216(9):1080-1090 - PubMed
  50. Science. 2013 Sep 20;341(6152):1359-65 - PubMed
  51. Expert Rev Vaccines. 2010 Dec;9(12):1371-84 - PubMed
  52. Mil Med. 2005 Apr;170(4 Suppl):3-11 - PubMed
  53. Clin Infect Dis. 2006 Nov 1;43 Suppl 3:S164-8 - PubMed
  54. Lancet Respir Med. 2016 May;4(5):399-406 - PubMed
  55. Expert Rev Vaccines. 2011 Jul;10(7):1021-35 - PubMed
  56. J Med Virol. 2000 Jan;60(1):77-85 - PubMed
  57. Hum Vaccin Immunother. 2013 Jun;9(6):1387-8 - PubMed
  58. Vaccine. 2012 Mar 2;30(11):1951-8 - PubMed
  59. Vaccine. 2005 Mar 18;23(17-18):2078-81 - PubMed
  60. Clin Infect Dis. 2014 Oct;59(7):962-8 - PubMed
  61. Expert Rev Vaccines. 2013 Aug;12(8):859-69 - PubMed
  62. Mil Med. 2005 Apr;170(4 Suppl):12-6 - PubMed
  63. Clin Infect Dis. 2007 Mar 15;44(6):850-6 - PubMed
  64. J Infect Dis. 2016 Sep 1;214(5):762-71 - PubMed
  65. J Infect Dis. 2004 Aug 15;190(4):702-6 - PubMed
  66. Vaccine. 2016 Jun 3;34(26):2976-2981 - PubMed
  67. N Engl J Med. 2013 Mar 21;368(12):1111-20 - PubMed
  68. Wkly Epidemiol Rec. 2016 Jan 4;91(4):33-51 - PubMed
  69. J Exp Med. 1969 Jun 1;129(6):1327-48 - PubMed
  70. Vaccine. 2008 May 12;26(20):2490-502 - PubMed
  71. N Engl J Med. 2015 Mar 19;372(12):1114-25 - PubMed
  72. Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130426 - PubMed
  73. Mil Med. 2010 Jul;175(7 Suppl):42-4 - PubMed
  74. Vaccine. 2000 Feb 14;18(15):1448-55 - PubMed
  75. Vaccine. 2007 Oct 10;25(41):7017-30 - PubMed
  76. Proc (Bayl Univ Med Cent). 2004 Oct;17(4):400-6 - PubMed
  77. MSMR. 2014 Nov;21(11):10-5 - PubMed
  78. Wien Klin Wochenschr. 2008;120(19-20 Suppl 4):15-9 - PubMed
  79. J Exp Med. 1969 Jun 1;129(6):1385-95 - PubMed
  80. Am J Trop Med Hyg. 1961 May;10:317-20 - PubMed
  81. J Infect Dis. 1995 Jun;171(6):1576-85 - PubMed
  82. Immunol Rev. 2017 Jan;275(1):245-261 - PubMed
  83. Emerg Infect Dis. 1999 Jul-Aug;5(4):531-3 - PubMed
  84. J Infect Dis. 1978 Nov;138(5):618-24 - PubMed
  85. MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57 - PubMed
  86. Lancet. 2014 Oct 11;384(9951):1358-65 - PubMed
  87. J Infect Dis. 1977 Dec;136 Suppl:S456-9 - PubMed
  88. Mil Med. 2005 Apr;170(4 Suppl):66-70 - PubMed
  89. MMWR Morb Mortal Wkly Rep. 2016 Mar 18;65(10):257-62 - PubMed
  90. N Engl J Med. 2012 Apr 5;366(14):1275-86 - PubMed
  91. Vaccine. 2015 Dec 10;33(50):7061-8 - PubMed
  92. J Infect Dis. 2017 Dec 16;216(suppl_10):S860-S867 - PubMed
  93. Rev Infect Dis. 1979 Nov-Dec;1(6):946-54 - PubMed
  94. Expert Opin Biol Ther. 2002 Dec;2(8):883-93 - PubMed
  95. N Engl J Med. 2009 Dec 3;361(23):2209-20 - PubMed
  96. Hum Vaccin Immunother. 2012 Aug;8(8):1126-8 - PubMed
  97. J Infect Dis. 2017 Dec 16;216(suppl_10):S857-S859 - PubMed
  98. Bull World Health Organ. 1990;68 Suppl:13-6 - PubMed
  99. Vaccine. 2013 Sep 23;31(41):4487-500 - PubMed
  100. PLoS One. 2010 Nov 15;5(11):e13983 - PubMed
  101. Clin Infect Dis. 1993 Nov;17(5):913-24 - PubMed
  102. N Engl J Med. 2008 Aug 7;359(6):603-12 - PubMed
  103. AIDS Res Hum Retroviruses. 2002 Nov 1;18(16):1235-7 - PubMed
  104. Vaccine. 2016 Jun 3;34(26):2915-2920 - PubMed
  105. Lancet Infect Dis. 2017 May;17(5):498-509 - PubMed
  106. AIDS. 1995 Sep;9(9):1061-5 - PubMed
  107. Epidemiol Rev. 2006;28:3-26 - PubMed
  108. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55 - PubMed

Publication Types